Oct 6, 9:11 AM ET
BioLife Solutions became a wholly owned subsidiary of Repligen after the two companies closed their merger on October 6, 2026. Each BioLife share was converted into 0.1442 Repligen shares plus $11.25 in cash, and BioLife stock is set to be suspended from Nasdaq and deregistered, so shareholders no longer hold a public BioLife stake.
- Each BioLife share converted into 0.1442 Repligen common shares plus $11.25 in cash, without interest.
- Mergers closed on October 6, 2026; BioLife stock to be suspended from Nasdaq at the close of business that day.
- Stockholders adopted the merger agreement at the October 5, 2026 special meeting: 40,910,337 for, 83,451 against, 807 abstaining.
- All BioLife directors and five named executive officers resigned effective at the First Merger Effective Time.
Read the filing on SEC.gov ↗
Aug 6, 4:08 PM ET
BioLife Solutions reported second-quarter 2026 revenue of $28.5 million, up 21% from a year earlier, and GAAP net income of $45.1 million, which includes a $42.4 million non-cash income tax benefit from the release of a valuation allowance. The company also disclosed a July 21, 2026 agreement under which Repligen will acquire BioLife for a total enterprise value of about $1.5 billion, after which BioLife will no longer be publicly traded, so shareholders' outcome depends on that deal closing.
- Q2 2026 revenue was $28.5 million, up $5.0 million or 21% from $23.4 million in Q2 2025 and up 4% from Q1 2026.
- GAAP net income was $45.1 million, or $0.92 per basic share, including the $42.4 million tax benefit; adjusted net income was $4.2 million.
- GAAP gross margin was 64% versus 65% a year earlier; adjusted EBITDA was $7.4 million, or 26% of revenue.
- Repligen will pay $11.25 in cash and 0.1442 Repligen shares per BioLife share; closing is expected in Q4 2026, subject to stockholder and regulatory approvals.
Read the filing on SEC.gov ↗
Jul 22, 5:17 PM ET
BioLife Solutions agreed on July 21, 2026 to be acquired by Repligen Corporation in a merger. Each BioLife share will receive $11.25 in cash and 0.1442 Repligen shares, which the press release values at $31.00 per share, a 24% premium to the 90-day VWAP through July 21, 2026. The deal is expected to close in the fourth quarter of 2026 and requires BioLife stockholder approval and other customary conditions.
- Consideration per BioLife share: $11.25 in cash plus 0.1442 Repligen common shares, valued at $31.00 total in the press release
- BioLife may owe Repligen a termination fee of $59,000,000 in specified circumstances
- Mergers expected to close in the fourth quarter of 2026; outside date January 31, 2027, subject to extension
- BioLife preliminary second-quarter 2026 revenue of $28.5 million, up 21% from $23.4 million; full results due August 6, 2026
Read the filing on SEC.gov ↗
May 7, 4:14 PM ET
BioLife Solutions reported unaudited first-quarter 2026 results, with revenue of $27.5 million, up 25% from $22.1 million a year earlier, and GAAP net income of $1.2 million, compared with $0.3 million. The company reiterated its full-year 2026 revenue guidance of $112.5 million to $115.0 million, which matters to shareholders because it signals the company expects to keep its growth pace for the year.
- Q1 2026 revenue was $27.5 million, up $5.4 million or 25% from $22.1 million in Q1 2025.
- GAAP net income was $1.2 million, or $0.02 per share, compared with $0.3 million, or $0.01 per share, in Q1 2025.
- Adjusted EBITDA was $6.2 million, or 22% of revenue, compared with $5.4 million, or 24% of revenue, a year earlier.
- 2026 revenue guidance of $112.5 million to $115.0 million, representing 17% to 20% growth, was reiterated; cash and marketable securities were $111.5 million at March 31, 2026.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.